The Real Reason Banks Don’t Like Bitcoin Jon Southurst

New Post Public Reply Private Reply Replies (0) Message Board
Ospreyeye
The Real Reason Banks Don’t Like Bitcoin
Jon Southurst (@southtopia) | Published on July 22, 2014


http://www.coindesk.com/real-reason-banks-dont-like-bitcoin/

Banks are reluctant to work with bitcoin, that fact has been well known in the community for some time. Until now, though, few concrete reasons have been given as to why.

New statements from a senior banking practitioner in Australia working in anti-money laundering (AML) and counter-terrorism financing (CTF), compliance could go some way to providing an explanation.

Banks around the world, particularly in the US, have been closing down accounts of bitcoin startups and even bitcoin-accepting businesses for over a year now. Even those that do work with bitcoin businesses are reluctant to be named in the media.

More conspiratorial theories say bitcoin’s destiny is to replace banks, and banks fear the competition. The real answer, however, could be the more mundane one of regulatory risk.

Worldwide regulatory environment

Australia’s banking and investment laws are similar to those in other Western, developed economies, so the reasons presented here are likely to be similar around the world.

The Financial Action Task Force on Money Laundering (FATF/GAFI) is an intergovernmental organization started in 1989 by the G7, and now has 34 members plus several regional associates.

Tasked with combating the financing of terrorist organizations, it is a key factor in AML/CTF regulation and policy setting among its members, meaning banks in those countries face similar legislative environments.

A banker gives reasons

The senior banking practitioner, who asked not to be named, attended a recent Bitcoin Professionals meetup in Sydney, organized by lawyer Reuben Bramanathan and entrepreneur Jason Williams of the Bitcoin Association of Australia. The banker explained the following: It is extremely risky and costly for banks to have bitcoin businesses on their books at the moment.

In addition to existing know-your-customer (KYC) requirements, the banker said, banks in Australia have a “know your customer’s customer” requirement.

New Customer Due Diligence rules, which started 1st June this year, impose a high standard on banks to identify their customers (including the difficult process of identifying beneficial ownership and control) and to maintain ongoing customer due diligence (CDD) and monitoring.

There are additional CDD requirements for accounts concerning “politically exposed persons“, or individuals with prominent public functions and their associates who may be susceptible to corruption.

Bitcoin and the definition of money

The problems for bitcoin begin with its legal status as ‘money’ or otherwise.

At present, the Anti-Money Laundering and Counter-Terrorism Financing Act in Australia does not include bitcoin businesses under its ‘designated services’ category. As a non-national currency, bitcoin would likely be defined as ‘e-money’ – and this is limited to “an internet-based electronic means of exchange that is backed by bullion or precious metal and is issued by a government body”.

The current law was written in 2006, before bitcoin had been released.

This limited definition of e-money means there can be no regulatory oversight from the Australian Transaction Reports and Analysis Centre (AUSTRAC), Australia’s primary regulator for AML/CTF issues.

This, in turn, means banks must play the role of regulators themselves, creating an enormous amount of extra work as they monitor and supervise their own due diligence.

More work, higher costs, bigger risks

The anonymous banker explained that extra work creates extra costs and, from a commercial point of view, the profit banks make from businesses does not cover the compliance costs.

Add to that the significant penalties they face if anything goes wrong, the lack of oversight increases risk levels to a point where banks consider it extremely dangerous to have a bitcoin business on their books, unless that business can show it is itself voluntarily compliant with all the AML/CTF rules.

If large banks struggle to deploy these kinds of resources, bitcoin startups will too.

Lawyer and digital currency specialist Amor Sexton told CoinDesk that, given all this, banks take the simpler option of just avoiding bitcoin altogether.

She said:

“Some, but very few, of the banks, are taking a rational and fair approach by assessing each businesses on a case-by-case basis. Others have decided that it is easier to exit all bitcoin businesses.

This is a very real and urgent concern for the bitcoin industry, as access to banking is an essential requirement for any business.”

The wall facing bitcoin

Banks in smaller countries, like Australia, must also comply with regulations in larger ones if it maintains relationships or has subsidiaries in other countries. Non-US banks must comply with US regulations if they have customers who are US citizens or formal relationships with US businesses, all of which adds another layer of compliance – and its associated costs and risks.

Although these reasons may not come as a surprise to many bitcoiners, especially those from the traditional finance industry, hearing them directly from a banking representative could help startups understand the prevailing attitude.

Bitcoin businesses, still a new phenomenon in the economy, have some way to go to prove their industry is every bit as trustworthy as others, and that will take time as well as campaigning.

In the meantime, industry groups like the Bitcoin Association of Australia and the newly-formed business lobby Australian Digital Currency Commerce Association (ADCCA) will be pressing the case locally, sharing their experience with associates worldwide.

Image via Paul Fleet / Shutterstock

AustraliaAustralia Bitcoin Associationbanking
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Aroa Biosurgery Reports Low Infection Rates: A Milestone

Updated Category News Views 1

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Continue Reading
Harbour BioMed Joins Stock Connect, Boosts Investor Access

Updated Category News Views 3

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Continue Reading
Clover's RSV Combo Vaccine Shows Promise in Trials

Updated Category News Views 1

In the biotech world, there's always a race. Clover Biopharmaceuticals is making strides with their RSV+hMPV vaccine candidate, especially for the elderly. Imagine those big leaps in development—all boosted by recent results from a Phase 2 trial down under in Australia. Key Findings of the Trial Immunogenicity Insights They're not messing around with these findings. The...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 12

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
ATTACK SHARK Partners with Cloud9 League Team

Updated Category News Views 2

Shaking Hands with Cloud9 ATTACK SHARK is jumping headfirst into the esports game, teaming up with Cloud9's League of Legends team. Now, before you roll your eyes at another corporate matchmaking play, consider the magic at play here. League of Legends isn't just any game; it's a titan in the esports universe, and partnering with Cloud9 offers a serious boost. It's not...

Continue Reading
Zendure, SolarFlow Pro Win Big at IFA 2026 Tech Awards

Updated Category News Views 2

Trophy Time for Zendure in Berlin The Berlin Chronicles of 2026 tell an interesting tale for Zendure—a tale where top honors and glowing recognition highlight its efforts in the sustainable energy arena. At the Global Product Technology Innovation Awards, Zendure's SolarFlow 4000 Mix Pro snagged the Gold for Sustainable Home Energy Storage System. Not only that, but...

Continue Reading
Media Forum Spotlights Asia-Pacific Cooperation

Updated Category News Views 3

The Opening Scene: A Gathering with Purpose Well, here we go, diving right into the latest shindig in Shenzhen at the Asia-Pacific Media Forum. Held in China's Guangdong province, they've rounded up over 400 reps from every corner of the globe, all chewing over one key theme: "Building a Path to Shared Prosperity for the Asia-Pacific Community." You could say it's a step...

Continue Reading
Fosun Pharma Hits the Buyback Button: What's Next?

Updated Category News Views 0

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 3

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading

Top 5 Most Recently Viewed Articles

Prologis Earnings Report: Investors' Key Insights and Analysis

Updated Category News Views 138

Understanding Prologis's Upcoming Quarterly Earnings Prologis (NYSE: PLD) is set to release its latest quarterly earnings report, and investors are eagerly awaiting the insights it will provide. As the company approaches its earnings announcement, analysts project an earnings per share (EPS) of $1.02, which serves as a benchmark for performance expectations. Investor...

Continue Reading
How Changing U.S. Jobs Report Affects Market Dynamics

Updated Category News Views 171

The recent U. S. employment report sent shockwaves through financial markets, reshaping how traders and investors eyed their portfolios. Stronger-than-expected job creation—with figures soaring over 100,000—meant one thing: the narrative on interest rates was about to change. Gone were the days of comfortably betting on rate cuts; now, everyone’s scrambling to...

Continue Reading
Suno Boosts Innovation for Creators by Acquiring WavTool

Updated Category News Views 157

Suno Boosts Innovation for Creators by Acquiring WavTool Suno has recently made a significant move in the music industry with their acquisition of WavTool. This strategic decision aims to enhance their offerings for songwriters and producers, enabling them to create music that resonates with a broader audience. By integrating WavTool's advanced capabilities into their...

Continue Reading
Leqembi's New IV Treatment Approval: A Milestone for Alzheimer’s Care

Updated Category News Views 274

Leqembi Approved for IV Maintenance Treatment BioArctic AB, a notable player in the biopharmaceutical sector, has made significant headlines with the approval of Leqembi (lecanemab) for intravenous (IV) maintenance treatment for Alzheimer’s disease in the United Kingdom. This groundbreaking decision was announced following rigorous evaluations by the Medicines and...

Continue Reading
Investors of ATYR, MLTX, BAX, and JHX Have Legal Options

Updated Category News Views 145

Overview of Class Action Lawsuits for ATYR, MLTX, BAX, JHX Attention investors! If you’ve invested in aTyr Pharma Inc. (NASDAQ: ATYR), MoonLake Immunotherapeutics (NASDAQ: MLTX), Baxter International, Inc. (NYSE: BAX), or James Hardie Industries plc (NYSE: JHX), it’s important to be aware of significant class action lawsuits affecting your investments. These companies...

Continue Reading